Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

摘要: In the Phase III PATRICIA study (NCT00122681), human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals) was highly efficacious against HPV-16/18 infections and precancerous lesions in women deoxyribose nucleic acid (DNA) negative seronegative at baseline. We present further data on efficacy (VE) total vaccinated cohort including who may have been exposed to infection before vaccination. with no evidence of current or previous (DNA seronegative), VE 90.3% (96.1% confidence interval: 87.3-92.6) 6-month persistent (PI), 91.9% (84.6-96.2) cervical intraepithelial neoplasia (CIN)1+ 94.6% (86.3-98.4) CIN2+ [97.7% (91.1-99.8) when using HPV type assignment algorithm (TAA)]. DNA but serological (seropositive), 72.3% (53.0-84.5) PI, 67.2% (10.9-89.9) CIN1+, 68.8% (-28.3-95.0) [88.5% (10.8-99.8) TAA]. negative), regardless their baseline status, 88.7% (85.7-91.1) 89.1% (81.6-94.0) CIN1+ 92.4% (84.0-97.0) [97.0% (90.6-99.5) were positive for one type, other type. The did not impact outcome time Vaccination generally well tolerated woman's status entry.